U.S. markets closed
  • S&P 500

    3,910.52
    -30.07 (-0.76%)
     
  • Dow 30

    32,423.15
    -308.05 (-0.94%)
     
  • Nasdaq

    13,227.70
    -149.84 (-1.12%)
     
  • Russell 2000

    2,185.69
    -81.16 (-3.58%)
     
  • Crude Oil

    57.40
    -4.16 (-6.76%)
     
  • Gold

    1,725.90
    -12.20 (-0.70%)
     
  • Silver

    25.10
    -0.67 (-2.60%)
     
  • EUR/USD

    1.1855
    -0.0084 (-0.70%)
     
  • 10-Yr Bond

    1.6380
    -0.0460 (-2.73%)
     
  • GBP/USD

    1.3756
    -0.0107 (-0.77%)
     
  • USD/JPY

    108.6020
    -0.2180 (-0.20%)
     
  • BTC-USD

    54,664.33
    -1,550.09 (-2.76%)
     
  • CMC Crypto 200

    1,093.98
    -5.83 (-0.53%)
     
  • FTSE 100

    6,699.19
    -26.91 (-0.40%)
     
  • Nikkei 225

    28,995.92
    -178.23 (-0.61%)
     

Why Ionis Pharmaceuticals Stock is Trading Lower Today

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

 

  Ionis Pharmaceuticals Stock Price And Volume Action

Ionis Pharmaceuticals (NASDAQ:IONS) is currently down 17.47% to a price of $46.29. Tuesday the stock has been traded at a volume of 2.55 million, about 283.92% of its recent 30-day volume average of 899.74 thousand.

Why It's Moving

Benzinga Pro's real-time breaking news service shows some insight into what is affecting shares: Ionis Pharmaceuticals shares are trading lower after the company announced its partner, Roche, has decided to discontinue dosing in the Phase III GENERATION HD1 study of tominersen in manifest Huntington's disease.

Further Analysis of Recent Price Action

The stock's 50-day moving average was $57.34 at the time this article was published. Over the past fifty-two weeks, the price has risen as high as $64.37 and fallen to a low of $39.32.

Benzinga Pro provides investors with timely and accurate explanations of why a stock is moving. Subscribe to receive real-time alerts explaining stock price movements. Click here to learn more.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.